Le Lézard
Classified in: Transportation, Health
Subjects: PDT, TDS, DIS, DEI

Robooter Showcases All Terrain Electric Wheelchair E60 Series at Naidex 2024 and Medtrade 2024


BIRMINGHAM, England, March 20, 2024 /PRNewswire/ -- Robooter, a leading innovator in the autonomous mobility solution is thrilled to announce its showcase and smart outdoor electric wheelchair at the Naidex 2024, held from March 20 to 21 in NEC Birmingham and on March 27-28, at the Medtrade Expo, Dallas, TX.

Robooter E60 and E60 pro-A outdoor foldable electric wheelchair at the Naidex and Medtrade Expo 2024

Expanding Mobility Solutions with E60 E60-A,E60 Pro and E60 Pro-A

E60 series is the first of its kind,smart,off-road power wheelchair launched by ROBOOTER. It delivers high endurance and fast driving speed with the perfect blend of design and function.

The E60 and E60-A models are equipped with 10-inch omnidirectional wheels, while the E60Pro and E60 Pro-A feature larger 12-inch wheels, conquering obstacles up to 8cm (3.1'') in height. 3 levels of reclinable backrest from 108°to 138°of E60-A and E60 Pro-A gives a comfortable sitting posture with multi choices.For E60-A and E60 Pro-A Flip-over armrest allows the user to sit onto the wheelchair more conveniently. Expandable armrest from 455-515mm (17.9''-20.3'')fits for different body shapes.

Foldable Outdoor Electric Wheelchair E60 Series is remotely controlled by app and can hold up to 150kg. IoT function makes GPS, SOS accessible.

The front independent suspension spring with strong spring coils and high-performance omnidirectional wheels of E60 series allow free movement in any direction, enhancing navigation in complex terrains and a variety of outdoor environments.

A message from overseas director Buji Jhang

Buji Jhang, Director of Overseas Sales and Marketing at Robooter, commented to PR Newswire:
'Omnidirectional wheels for E60, E60-A, E60Pro and E60 Pro-A, indeed, enable vehicles to rotate freely in extremely tight spaces without the need for a traditional turning radius.

This technology is particularly suited for robots or vehicles that need to operate in confined spaces, such as lower limb mobility devices and some advanced automotive technologies.'

Booth Information
Naidex 2024:
Date: 20? 21 March 2024
Location: NEC Birmingham
Booth number: E136, hall 20

Medtrade 2024:
Date: 27? 28 March 2024
Location: Kay Bailey Hutchison Convention Center  ?  Dallas, TX
Booth number: 201
More information about Robooter' involvement at Naidex and Medtrade Expo 2024 can be found at www.robooter.com.

About ROBOOTER

Robooter is proud to offer innovative and reliable electric wheelchairs designed to empower your mobility and independence. Our team is committed to creating high-quality products that allow you to navigate the world with ease and comfort.

SOURCE ROBOOTER


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: